27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Measuring usability and UX in cognitive intervention technologies for older adults with MCI or dementia provides an integrated view that can contribute to their development according to the needs and characteristics of the target population. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Daily driving is a multi-faceted, real-world, behavioral measure of cognitive functioning requiring multiple cognitive domains working synergistically to complete this instrumental activity of daily living. 1 key finding →
Design: longitudinal study Participants: 186 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Due to the growing number of older adults with cognitive impairment, it is essential to delay the onset and progression of cognitive decline and promote a healthy lifestyle. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Five hundred and forty five patients from 67 NH units were included and randomized to the intervention ( N = 297; 36 units) and control group ( N = 248; 31 units). 5 key findings →
Participants: 72 Evidence: high
Full summary, score breakdown and related studies → Original source
Regular musical activity as a complex multimodal lifestyle activity is proposed to be protective against age-related cognitive decline and Alzheimer's disease. 2 key findings →
Design: cross-sectional Participants: 70 Evidence: moderate
Full summary, score breakdown and related studies → Original source
PLWD also commonly experience social isolation (Shen et al., 2022), poorer physical function (Jehu et al., 2024a), worsened behavioral and psychological symptoms (Cerejeira et al., 2012), poorer quality of life (Cerejeira et al., 2012), and reduced access to healthcare (Mitchell et al., 2016) compared to older adults without dementia. 5 key findings →
Design: randomized controlled trial Participants: 21 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Depression and related neurobehavioral symptoms are common features of Alzheimer's disease and other dementias. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
We evaluated a digital cognitive assessment platform, Philips IntelliSpace Cognition, in a case-control study of patients diagnosed with mild cognitive impairment (MCI) and cognitively normal (CN) older adults. 2 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
A high Pearson correlation coefficient of 0.77 (CI = 0.63-0.86) was observed between the two scores. 5 key findings →
Participants: 55 Evidence: low
Full summary, score breakdown and related studies → Original source
Twenty-five of 33 (75.8%) participants in the qigong group and 26 of 33 (78.8%) participants in the control group completed the 1-year exercise programs. 4 key findings →
Participants: 33 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Language assessment has a crucial role in the clinical diagnosis of several neurodegenerative diseases. 5 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source
Area deprivation index (ADI), a tool used to capture the multidimensional neighborhood socioeconomic disadvantage across populations, is highly relevant to the field of aging and Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These findings suggest that HB-CCT via Neurotablet can effectively enhance specific cognitive abilities in PD, supporting the role of digital, home-based interventions as feasible strategies to mitigate cognitive decline. 4 key findings →
Design: post-hoc analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our results will provide new evidence of the efficacy of an innovative multi-component intervention integrating IVR and telemedicine in SCD individuals. 2 key findings →
Participants: 75 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The paper discusses according to prevailing diagnostic systems and algorithms, which cognitive domains that are relevant to investigate, which tests that may be relevant, what kind of norms have satisfactory quality, which cut-off scores do best balance sensitivity and specificity in a neurodiagnostic context, and what kind of conclusions and recommendations that can be drawn from neuropsychological findings. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
To date, the impact of cognitive therapies on patients with dementia and mild cognitive impairment (MCI) has been studied in terms of cognition, quality of life and activities of daily living rather than in the context of neuropsychiatric symptoms (NPS). 5 key findings →
Participants: 4,089 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
FTD patients performed significantly worse than HCs in most of the subtests of the basic emotion recognition batteries, where, instead, AD patients were significantly impaired only when required to match emotional facial expression in different individuals (subtask of the FERB). 5 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research supporting cognitive reserve theory suggests that engaging in a variety of cognitive, social, and physical activities may serve as protective factors against age-related changes in mental functioning, especially if the activities are cognitively engaging. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The human lifespan has expanded drastically in the last few centuries, due to improvements in sanitation, medicine, and nutrition, but with this increase in longevity comes higher rates of cognitive pathology such as mild cognitive impairment (MCI) and dementia; the latter is estimated to reach more than 75 million people by 2030. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Decreased olfactory function is very common in the older population, being present in over half of those between the ages of 65 and 80 years and in over three quarters of those over the age of 80 years. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
It was found that individuals with Alzheimer’s disease (AD) have poorer balance and a higher risk of falls compared to healthy individuals. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
No significant differences were found between the in-person and remote groups in terms of age, education, or gender. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The focus of this review is on driving neuroplasticity in a positive direction using evidence-based interventions that also have the potential to improve general health. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Across CTT studies, findings ranged from two-factor to hierarchical multi-factor models, with a general cognitive factor frequently emerging. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Beyond these practical challenges, caregivers often endure significant physical exhaustion and sleep deprivation from the unrelenting demands of caregiving, which can lead to chronic fatigue and deteriorating health (Liu et al., 2022; Mao et al., 2024). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →